ASCP review parses antidepressant discontinuation symptoms

A new review from the American Society of Clinical Psychopharmacology says acute antidepressant discontinuation symptoms are real and usually short-lived, but evidence is much less certain for delayed or persistent symptoms. The paper aims to help clinicians separate withdrawal effects from relapse and other causes after patients stop SSRIs or SNRIs.

Why it matters: - Antidepressant stopping decisions affect millions of patients who may need a taper, a medication switch or long-term treatment. - The review argues that confusing withdrawal with relapse, distress or other causes can lead to poor care decisions. - Clearer distinctions could help clinicians individualize deprescribing and avoid mislabeling symptoms.

What happened: - Members of the American Society of Clinical Psychopharmacology published a review in the Journal of Clinical Psychiatry on symptoms after antidepressant cessation. - The paper examines what current evidence shows, and does not show, about symptoms that follow stopping antidepressants. - The review was published online Aug. 6, 2026. - The article citation is: Goldberg JF, Crismon ML, Goodman DW, et al., "When do physical symptoms after antidepressant cessation reflect pharmacodynamic versus non-pharmacodynamic clinical phenomena?" Read the study.

The details: - Meta-analyses cited in the review estimate a placebo-subtracted rate of about 8% to 28% for physical discontinuation symptoms in people with major depressive disorder or anxiety disorders who abruptly stop a short half-life SSRI or SNRI after more than one month of treatment. - Typical symptoms include dizziness, nausea, vertigo, nervousness, insomnia, imbalance, sensory disturbances such as "brain zaps" and hyperarousal. - The review says these acute symptoms generally resolve within one to two weeks. - Slow dose tapers over several weeks are described as routine management. - The authors say acute antidepressant discontinuation symptoms occur in about one-third or fewer of people who stop an SSRI or SNRI. - The review says antidepressant discontinuation should be individualized, and some patients may need a slower-than-typical taper. - Clinical depression often recurs and sometimes requires indefinite or lifelong treatment. - Clinicians are urged to evaluate physical and emotional symptoms after stopping antidepressants for possible relapse of an underlying mental health condition.

Between the lines: - The review draws a sharp line between well-established acute discontinuation symptoms and the more controversial idea of delayed or protracted symptoms. - The authors say evidence for delayed or persistent symptoms is substantially less definitive. - They report finding no established physiological mechanism that adequately explains symptoms that newly appear long after the antidepressant has left the body. - The paper warns that attributing symptoms only to withdrawal may overlook recurrence, psychological distress or expectancy bias. - The authors say that kind of misattribution could feed anti-medicine sentiment and discourage patients from using beneficial treatment.

What's next: - ASCP says the review is meant to push more research on who should receive antidepressants, when they should be prescribed and how they should be deprescribed. - The organization says future work should improve quality of life and strengthen informed patient care. - Clinicians will likely continue relying on symptom timing, taper history and clinical context when deciding whether complaints reflect withdrawal or relapse.

The bottom line: - Acute antidepressant discontinuation symptoms are real, common enough to plan for and usually brief. - Persistent or delayed symptoms remain much less certain, and the review says clinicians should keep searching for other explanations before labeling them withdrawal.